Efficacy of Dupilumab with Concomitant Topical Calcineurin Inhibitors Treatment for Preschool Children with Atopic Dermatitis: a Retrospective Cohort Study

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2025 Jan 6

PMID 39757933

Authors

Wu Liming

Kamran Ali

Affiliations

Soon will be listed here.

Abstract

Background/objective: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that typically occurs in childhood/infancy and is associated with complications like extracutaneous atopic morbidity. Providing systemic treatment for pediatric AD patients with unmet comprehensive medical needs remains challenging. We present a cohort study describing the efficacy and safety of dupilumab combined with topical calcineurin inhibitors (TCI) in children with moderate-to-severe atopic dermatitis under the age of 6 years.

Methods: A retrospective cohort study was conducted at a single center to analyze the use of dupilumab in combination with topical calcineurin inhibitors (TCI) in children aged 6 years and under moderate-to-severe AD that was inadequately controlled with topical therapy.

Results: Overall, 23 preschool children (mean [] age, 4.78 [1.278] years); 10 boys (43.5%) and 13 girls (56.5%) received 300 mg dupilumab every four weeks and TCI. The primary outcome, the average Eczema Area and Severity Index (EASI) percentage reduction from baseline, was -70.85%. Significant improvement was also observed in secondary outcomes: caregiver-reported Peak Pruritus numerical rating scale (P-NRS) (-77.73%), Body Surface Area (BSA) (-62.11%), and Investigators Global Assessment (IGA) (-36.23%) at week 16. A 1-2 grade decrease in IGA after 16 weeks of treatment was achieved by 91.3% of patients. There was a significant improvement in P-NRS and EASI scores from baseline to week 16. Injection-site reaction (one patient) and facial redness (two patients) were recorded. No severe drug-related adverse events were observed.

Conclusion: This study demonstrated that the combination of dupilumab and TCIs improved symptoms and quality of life in preschoolers with moderate-to-severe AD.

References

Zhao Y, Wu L, Lu Q, Gao X, Zhu X, Yao X . The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2021; 186(4):633-641. PMC: 9298048. DOI: 10.1111/bjd.20690. View

Simpson E, Paller A, Siegfried E, Boguniewicz M, Sher L, Gooderham M . Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2019; 156(1):44-56. PMC: 6865265. DOI: 10.1001/jamadermatol.2019.3336. View

Harb H, Chatila T . Mechanisms of Dupilumab. Clin Exp Allergy. 2019; 50(1):5-14. PMC: 6930967. DOI: 10.1111/cea.13491. View

Simpson E, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham N . Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016; 74(3):491-8. DOI: 10.1016/j.jaad.2015.10.043. View

de Bruin-Weller M, Thaci D, Smith C, Reich K, Cork M, Radin A . Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III.... Br J Dermatol. 2017; 178(5):1083-1101. DOI: 10.1111/bjd.16156. View

Agache I, Akdis C, Akdis M, Brockow K, Chivato T, Del Giacco S . EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021; 76(4):988-1009. DOI: 10.1111/all.14690. View

Stander S . Atopic Dermatitis. N Engl J Med. 2021; 384(12):1136-1143. DOI: 10.1056/NEJMra2023911. View

Mullard A . FDA approves dupilumab for severe eczema. Nat Rev Drug Discov. 2017; 16(5):305. DOI: 10.1038/nrd.2017.90. View

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather J, Weisman J, Pariser D . Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10086):2287-2303. DOI: 10.1016/S0140-6736(17)31191-1. View

10.

Silverberg J . Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019; 123(2):144-151. DOI: 10.1016/j.anai.2019.04.020. View

11.

Mikhaylov D, Ungar B, Renert-Yuval Y, Guttman-Yassky E . Oral Janus kinase inhibitors for atopic dermatitis. Ann Allergy Asthma Immunol. 2023; 130(5):577-592. DOI: 10.1016/j.anai.2023.01.020. View

12.

Wu L, Ali K, Qiu Y, Li M, Da J . Dupilumab-induced Acute Generalized Exanthematous Pustulosis in a 17-year-old Female Chinese Patient with Atopic Dermatitis. Acta Derm Venereol. 2022; 102:adv00743. PMC: 9558754. DOI: 10.2340/actadv.v102.1079. View

13.

Paller A, Siegfried E, Simpson E, Cork M, Lockshin B, Kosloski M . A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2020; 35(2):464-475. PMC: 7894166. DOI: 10.1111/jdv.16928. View

14.

Cork M, Thaci D, Eichenfield L, Arkwright P, Hultsch T, Davis J . Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2019; 182(1):85-96. PMC: 6972638. DOI: 10.1111/bjd.18476. View

15.

Na C, Chung J, Simpson E . Quality of Life and Disease Impact of Atopic Dermatitis and Psoriasis on Children and Their Families. Children (Basel). 2019; 6(12). PMC: 6955769. DOI: 10.3390/children6120133. View

16.

Da J, Ali K, Lu K, Lou H, Qiu Y, Shan J . Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series. Clin Exp Dermatol. 2021; 47(2):423-425. DOI: 10.1111/ced.14925. View

17.

Paller A, Tan J, Bagel J, Rossi A, Shumel B, Zhang H . IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis. Br J Dermatol. 2021; 186(3):496-507. PMC: 9303952. DOI: 10.1111/bjd.20872. View

18.

Paller A, Siegfried E, Thaci D, Wollenberg A, Cork M, Arkwright P . Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020; 83(5):1282-1293. DOI: 10.1016/j.jaad.2020.06.054. View

19.

Simpson E, Bieber T, Guttman-Yassky E, Beck L, Blauvelt A, Cork M . Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016; 375(24):2335-2348. DOI: 10.1056/NEJMoa1610020. View

20.

Calabrese G, Licata G, Gambardella A, DE Rosa A, Alfano R, Argenziano G . Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?. Dermatol Pract Concept. 2022; 12(1):e2022155. PMC: 8824598. DOI: 10.5826/dpc.1201a155. View